Skip to content
Sign In

Main Navigation

James Sharp Logo
  • Individuals
    Individuals

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

    Investing

    • Inheritance TaxInheritance Tax
  • Charities & Trustees
    Charities & Trustees

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

  • Companies
    Companies

    Choose Your Level of Service

    • Discretionary ServiceDiscretionary Service
    • Execution Only ServiceExecution Only Service

  • News & Insights
    • News & Insights
    • Current Research Coverage List
  • About Us
    • About Us
    • Our People
  • Client Area and Conectus Portal
  • Contact Us

Market News - Page 254

24 August 2022

Camellia plc Trading Update for the Year So Far 2022

Camellia Plc (CAM.L) issues the following update on trading for the year and confirms the interim results release date….

23 August 2022

JP Morgan American INvestment Trust Unaudited Half-Year Results 2022

Unaudited half-year results for the six months ended 30th June 2022…

19 August 2022

HICL Infrastructure Acquisition Activity UK PPP

“HICL” or the “Company” and, together with its subsidiaries, the “Group”, the London-listed infrastructure investment company managed by InfraRed Capital Partners Limited (“InfraRed” or the “Investment Manager”)….

17 August 2022

Colefax Group plc Preliminary Results 2022

Preliminary Results for the year ended 30 April 2022…

17 August 2022

GSK plc: US FDA Accepts New Drug Application for Momelotinib

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action that may address the significant unmet medical needs of myelofibrosis patients with anaemia. …

17 August 2022

GSK plc Statement: Zantac (ranitidine) Litigation Update

Statement: Zantac (ranitidine) U.S. litigation   Notice of Voluntary Dismissal to be filed in Bayer case, first scheduled Zantac trial GSK did not settle Plaintiff…

16 August 2022

Astrazeneca plc sNDA Granted Priority Review in the US

AstraZeneca's supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC)….

16 August 2022

LondonMetric Property Disposal of Four Assets for £26m

16 August 2022 LONDONMETRIC PROPERTY PLC LONDONMETRIC SELLS FOUR ASSETS FOR £26 MILLION   LondonMetric Property Plc (“LondonMetric”) has sold four assets, in two separate…

Posts navigation

  • «
  • 1
  • …
  • 252
  • 253
  • 254
  • 255
  • 256
  • …
  • 858
  • »

Home > Market News > Page 254

James Sharp white Logo
Sign In
Linkedin Icon

The Exchange
5 Bank Street
Bury, Lancashire
BL9 0DN

Tel: 0161 764 4043

Fax: 0161 764 1628

Email: mail@jamessharp.co.uk

Linkedin Icon

James Sharp & Co is a trading name
of James Sharp & Co LLP (0C422665)

Members of the LLP are referred to as Partners

  • Downloads & Resources
  • Complaints
  • Financial Compensation Scheme
  • Client Area and Conectus Portal

  • Cyber Essentials Certification
  • Website Terms & Conditions
  • Privacy Policy
  • Cookie policy
  • Consent Preferences

Email Newsletter Sign-up

Consent(Required)
What we do with you information. Find out more
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© Copyright 2010-2025. All rights reserved. James Sharp & Co. Authorised & Regulated by the Financial Conduct Authority
Member of the London Stock Exchange - Member of the Aquis Stock Exchange - Member of PIMFA

Website by ICG